231 related articles for article (PubMed ID: 35501528)
1. A Critical Overview of the Biological Effects of Excipients (Part II): Scientific Considerations and Tools for Oral Product Development.
Martinez MN; Wu F; Sinko B; Brayden DJ; Grass M; Kesisoglou F; Stewart A; Sugano K
AAPS J; 2022 May; 24(3):61. PubMed ID: 35501528
[TBL] [Abstract][Full Text] [Related]
2. A Critical Overview of the Biological Effects of Excipients (Part I): Impact on Gastrointestinal Absorption.
Martinez MN; Sinko B; Wu F; Flanagan T; Borbás E; Tsakalozou E; Giacomini KM
AAPS J; 2022 May; 24(3):60. PubMed ID: 35501614
[TBL] [Abstract][Full Text] [Related]
3. Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: impact on bioequivalence.
García-Arieta A
Eur J Pharm Sci; 2014 Dec; 65():89-97. PubMed ID: 25236823
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Excipient Risk in BCS Class I and III Biowaivers.
Metry M; Polli JE
AAPS J; 2022 Jan; 24(1):20. PubMed ID: 34988701
[TBL] [Abstract][Full Text] [Related]
5. Potential for pharmaceutical excipients to impact absorption: A mechanistic review for BCS Class 1 and 3 drugs.
Flanagan T
Eur J Pharm Biopharm; 2019 Aug; 141():130-138. PubMed ID: 31128247
[TBL] [Abstract][Full Text] [Related]
6. Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics.
Pade D; Jamei M; Turner DB; Mistry B; Martinez MN
Eur J Pharm Biopharm; 2019 Aug; 141():191-209. PubMed ID: 31150808
[TBL] [Abstract][Full Text] [Related]
7. Effect of excipients on oral absorption process according to the different gastrointestinal segments.
Ruiz-Picazo A; Lozoya-Agullo I; González-Álvarez I; Bermejo M; González-Álvarez M
Expert Opin Drug Deliv; 2021 Aug; 18(8):1005-1024. PubMed ID: 32842776
[TBL] [Abstract][Full Text] [Related]
8. The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs.
Dahlgren D; Roos C; Johansson P; Tannergren C; Lundqvist A; Langguth P; Sjöblom M; Sjögren E; Lennernäs H
Int J Pharm; 2018 Aug; 547(1-2):158-168. PubMed ID: 29758344
[TBL] [Abstract][Full Text] [Related]
9. Boosting drug bioavailability in men but not women through the action of an excipient.
Mai Y; Ashiru-Oredope DAI; Yao Z; Dou L; Madla CM; Taherali F; Murdan S; Basit AW
Int J Pharm; 2020 Sep; 587():119678. PubMed ID: 32710919
[TBL] [Abstract][Full Text] [Related]
10. Impact of excipient interactions on drug bioavailability from solid dosage forms.
Panakanti R; Narang AS
Pharm Res; 2012 Oct; 29(10):2639-59. PubMed ID: 22610283
[TBL] [Abstract][Full Text] [Related]
11. Considerations for Determining Direct Versus Indirect Functional Effects of Solubilizing Excipients on Drug Transporters for Enhancing Bioavailability.
Lavan M; Knipp G
J Pharm Sci; 2020 Jun; 109(6):1833-1845. PubMed ID: 32142715
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Excipients on the Permeability of BCS Class III Compounds and Implications for Biowaivers.
Parr A; Hidalgo IJ; Bode C; Brown W; Yazdanian M; Gonzalez MA; Sagawa K; Miller K; Jiang W; Stippler ES
Pharm Res; 2016 Jan; 33(1):167-76. PubMed ID: 26286187
[TBL] [Abstract][Full Text] [Related]
13. The Effects of Pharmaceutical Excipients on Gastrointestinal Tract Metabolic Enzymes and Transporters-an Update.
Zhang W; Li Y; Zou P; Wu M; Zhang Z; Zhang T
AAPS J; 2016 Jul; 18(4):830-43. PubMed ID: 27184579
[TBL] [Abstract][Full Text] [Related]
14. Oral Absorption Promoters: Opportunities, Issues, and Challenges.
Yewale C; Patil S; Kolate A; Kore G; Misra A
Crit Rev Ther Drug Carrier Syst; 2015; 32(5):363-87. PubMed ID: 26559432
[TBL] [Abstract][Full Text] [Related]
15. In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects.
Sjögren E; Abrahamsson B; Augustijns P; Becker D; Bolger MB; Brewster M; Brouwers J; Flanagan T; Harwood M; Heinen C; Holm R; Juretschke HP; Kubbinga M; Lindahl A; Lukacova V; Münster U; Neuhoff S; Nguyen MA; Peer Av; Reppas C; Hodjegan AR; Tannergren C; Weitschies W; Wilson C; Zane P; Lennernäs H; Langguth P
Eur J Pharm Sci; 2014 Jun; 57():99-151. PubMed ID: 24637348
[TBL] [Abstract][Full Text] [Related]
16. Biopharmaceutical aspects and implications of excipient variability in drug product performance.
Zarmpi P; Flanagan T; Meehan E; Mann J; Fotaki N
Eur J Pharm Biopharm; 2017 Feb; 111():1-15. PubMed ID: 27845182
[TBL] [Abstract][Full Text] [Related]
17. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
O'Shea JP; Faisal W; Ruane-O'Hora T; Devine KJ; Kostewicz ES; O'Driscoll CM; Griffin BT
Eur J Pharm Biopharm; 2015 Oct; 96():207-16. PubMed ID: 26215636
[TBL] [Abstract][Full Text] [Related]
18. The Provisional No-Effect Threshold of Sugar Alcohols on Oral Drug Absorption Estimated by Physiologically Based Biopharmaceutics Model.
Yamane M; Matsui K; Sugihara M; Tokunaga Y
J Pharm Sci; 2021 Jan; 110(1):467-477. PubMed ID: 32470348
[TBL] [Abstract][Full Text] [Related]
19. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.
Bergström CA; Holm R; Jørgensen SA; Andersson SB; Artursson P; Beato S; Borde A; Box K; Brewster M; Dressman J; Feng KI; Halbert G; Kostewicz E; McAllister M; Muenster U; Thinnes J; Taylor R; Mullertz A
Eur J Pharm Sci; 2014 Jun; 57():173-99. PubMed ID: 24215735
[TBL] [Abstract][Full Text] [Related]
20. Use of sorbitol as pharmaceutical excipient in the present day formulations - issues and challenges for drug absorption and bioavailability.
Dash RP; Srinivas NR; Babu RJ
Drug Dev Ind Pharm; 2019 Sep; 45(9):1421-1429. PubMed ID: 31271324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
